Subtype-selective up-regulation of human saphenous vein beta 2-adrenoceptors by chronic beta-adrenoceptor antagonist treatment
- PMID: 2567967
- DOI: 10.1007/BF00736065
Subtype-selective up-regulation of human saphenous vein beta 2-adrenoceptors by chronic beta-adrenoceptor antagonist treatment
Abstract
To study beta-adrenoceptor antagonist-induced changes in human vascular beta-adrenoceptors, we determined the effects of chronic treatment with different beta-adrenoceptor antagonists without intrinsic sympathomimetic activity (ISA) on beta 2-adrenoceptor density (assessed by (-)-[125I]-iodopindolol binding) in human saphenous vein membranes obtained from patients undergoing coronary artery bypass grafting. In patients chronically treated with the non-selective beta-adrenoceptor antagonists propranolol or sotalol, the density of saphenous vein beta 2-adrenoceptors was significantly higher than in control (i.e. patients not treated with beta-adrenoceptor antagonists), whereas in patients chronically treated with the selective beta 1-adrenoceptor antagonists metoprolol or bisoprolol it was not different from control. It is concluded that beta-adrenoceptor antagonists without ISA increase human saphenous vein beta 2-adrenoceptors in a subtype-selective fashion.
Similar articles
-
Chronic beta-adrenoceptor antagonist treatment modulates human cardiac and vascular beta-adrenoceptor density in a subtype-selective fashion.J Hypertens Suppl. 1988 Dec;6(4):S497-500. doi: 10.1097/00004872-198812040-00157. J Hypertens Suppl. 1988. PMID: 2907348
-
Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment.Br J Pharmacol. 1988 Jul;94(3):685-92. doi: 10.1111/j.1476-5381.1988.tb11576.x. Br J Pharmacol. 1988. PMID: 2902891 Free PMC article.
-
Subtype-selective modulation of human beta 1- and beta 2-adrenoceptor function by beta-adrenoceptor agonists and antagonists.Clin Physiol Biochem. 1990;8 Suppl 2:11-7. Clin Physiol Biochem. 1990. PMID: 1982757 Review.
-
Atypical responses of rat ileum to pindolol, cyanopindolol and iodocyanopindolol.Br J Pharmacol. 1996 Feb;117(4):712-6. doi: 10.1111/j.1476-5381.1996.tb15248.x. Br J Pharmacol. 1996. PMID: 8646418 Free PMC article.
-
Differential changes in lymphocyte beta 2-adrenoceptor density by beta-blocker administration: role of intrinsic sympathomimetic activity.J Cardiovasc Pharmacol. 1986;8 Suppl 4:S93-6. J Cardiovasc Pharmacol. 1986. PMID: 2427860
Cited by
-
Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure.Naunyn Schmiedebergs Arch Pharmacol. 2007 Feb;374(5-6):361-72. doi: 10.1007/s00210-006-0125-7. Epub 2007 Jan 11. Naunyn Schmiedebergs Arch Pharmacol. 2007. PMID: 17216434 Review.
-
Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers.Eur J Clin Pharmacol. 1990;39(5):447-51. doi: 10.1007/BF00280934. Eur J Clin Pharmacol. 1990. PMID: 1963844
-
Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man.Br J Clin Pharmacol. 2001 Jun;51(6):583-9. doi: 10.1046/j.0306-5251.2001.01404.x. Br J Clin Pharmacol. 2001. PMID: 11422018 Free PMC article. Clinical Trial.
-
Does treatment with beta-adrenergic blocking agents cause a decrease in beta 2-adrenoceptor affinity?Eur J Clin Pharmacol. 1992;42(6):613-8. doi: 10.1007/BF00265924. Eur J Clin Pharmacol. 1992. PMID: 1352497 Clinical Trial.